Pyrrole butyric acid derivatives as inhibitors of steroid 5 alpha-reductase. 1997

M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
Medicinal Chemistry Laboratory, Sumitomo Metal Industries, Ltd., Kyoto, Japan.

A series of pyrrole butyric acid derivatives was synthesized and evaluated for inhibitory activity on human and rat steroid 5 alpha-reductase in vitro and ex vivo. 3-Benzoyl-4-alkylpyrrole-1-butyric acids and 1-methyl-2-alkyl-3-benzoylpyrrole-5-butyric acid derivatives were effective inhibitors. Structure activity relationships were evaluated among the 37 compounds synthesized. Compound 37 (HQL-1069) shows potent inhibitory activities against both rat and human 5 alpha-reductase.

UI MeSH Term Description Entries
D008297 Male Males
D008968 Molecular Conformation The characteristic three-dimensional shape of a molecule. Molecular Configuration,3D Molecular Structure,Configuration, Molecular,Molecular Structure, Three Dimensional,Three Dimensional Molecular Structure,3D Molecular Structures,Configurations, Molecular,Conformation, Molecular,Conformations, Molecular,Molecular Configurations,Molecular Conformations,Molecular Structure, 3D,Molecular Structures, 3D,Structure, 3D Molecular,Structures, 3D Molecular
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011758 Pyrroles Azoles of one NITROGEN and two double bonds that have aromatic chemical properties. Pyrrole
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005347 Fibroblasts Connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules. Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
December 1996, Journal of medicinal chemistry,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
August 1999, Chemical & pharmaceutical bulletin,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
January 2019, Assay and drug development technologies,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
April 1999, Chemical & pharmaceutical bulletin,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
July 1995, Journal of medicinal chemistry,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
February 1993, Journal of medicinal chemistry,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
March 1995, Archiv der Pharmazie,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
March 1992, The Journal of steroid biochemistry and molecular biology,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
December 1994, Acta urologica Belgica,
M Kato, and K Komoda, and A Namera, and Y Sakai, and S Okada, and A Yamada, and K Yokoyama, and E Migita, and Y Minobe, and T Tani
January 2001, Advances in protein chemistry,
Copied contents to your clipboard!